BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 35487312)

  • 1. Therapeutic bispecific antibodies against intracellular tumor antigens.
    Xu G; Luo Y; Wang H; Wang Y; Liu B; Wei J
    Cancer Lett; 2022 Jul; 538():215699. PubMed ID: 35487312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors Affecting the Cancer Immunotherapeutic Efficacy of T Cell Bispecific Antibodies and Strategies for Improvement.
    Long M; Mims AS; Li Z
    Immunol Invest; 2022 Nov; 51(8):2176-2214. PubMed ID: 36259611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.
    Hong Y; Nam SM; Moon A
    Arch Pharm Res; 2023 Mar; 46(3):131-148. PubMed ID: 36877356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.
    Fournier P; Schirrmacher V
    BioDrugs; 2013 Feb; 27(1):35-53. PubMed ID: 23329400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming tumor heterogeneity by ex vivo arming of T cells using multiple bispecific antibodies.
    Park JA; Cheung NV
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy.
    Zhang T; Lin Y; Gao Q
    Cancer Biol Med; 2023 Mar; 20(3):181-95. PubMed ID: 36971124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bispecific antibodies targeting CTLA-4: game-changer troopers in cancer immunotherapy.
    Farhangnia P; Ghomi SM; Akbarpour M; Delbandi AA
    Front Immunol; 2023; 14():1155778. PubMed ID: 37441075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bispecific antibody based therapeutics: Strengths and challenges.
    Thakur A; Huang M; Lum LG
    Blood Rev; 2018 Jul; 32(4):339-347. PubMed ID: 29482895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy.
    Huang S; van Duijnhoven SMJ; Sijts AJAM; van Elsas A
    J Cancer Res Clin Oncol; 2020 Dec; 146(12):3111-3122. PubMed ID: 32989604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials.
    Hosseini SS; Khalili S; Baradaran B; Bidar N; Shahbazi MA; Mosafer J; Hashemzaei M; Mokhtarzadeh A; Hamblin MR
    Int J Biol Macromol; 2021 Jan; 167():1030-1047. PubMed ID: 33197478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T Cell-Redirecting Strategies to 'STAb' Tumors: Beyond CARs and Bispecific Antibodies.
    Blanco B; Compte M; Lykkemark S; Sanz L; Alvarez-Vallina L
    Trends Immunol; 2019 Mar; 40(3):243-257. PubMed ID: 30827461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bispecific antibodies revolutionizing breast cancer treatment: a comprehensive overview.
    Lan HR; Chen M; Yao SY; Chen JX; Jin KT
    Front Immunol; 2023; 14():1266450. PubMed ID: 38111570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics.
    Li H; Er Saw P; Song E
    Cell Mol Immunol; 2020 May; 17(5):451-461. PubMed ID: 32313210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies.
    Lejeune M; Köse MC; Duray E; Einsele H; Beguin Y; Caers J
    Front Immunol; 2020; 11():762. PubMed ID: 32457743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment.
    Bock AM; Nowakowski GS; Wang Y
    Curr Treat Options Oncol; 2022 Feb; 23(2):155-170. PubMed ID: 35182296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T Cell-Activating Bispecific Antibodies in Cancer Therapy.
    Trabolsi A; Arumov A; Schatz JH
    J Immunol; 2019 Aug; 203(3):585-592. PubMed ID: 31332079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current landscape and future directions of bispecific antibodies in cancer immunotherapy.
    Wei J; Yang Y; Wang G; Liu M
    Front Immunol; 2022; 13():1035276. PubMed ID: 36389699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioassay Development for Bispecific Antibodies-Challenges and Opportunities.
    Register AC; Tarighat SS; Lee HY
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bispecific antibodies for targeted delivery of anti-cancer therapeutic agents: A review.
    Beishenaliev A; Loke YL; Goh SJ; Geo HN; Mugila M; Misran M; Chung LY; Kiew LV; Roffler S; Teo YY
    J Control Release; 2023 Jul; 359():268-286. PubMed ID: 37244297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific targeting immunotherapy of cancer with bispecific antibodies.
    Kudo T; Suzuki M; Katayose Y; Shinoda M; Sakurai N; Kodama H; Ichiyama M; Takemura S; Yoshida H; Saeki H; Saijyo S; Takahashi J; Tominaga T; Matsuno S
    Tohoku J Exp Med; 1999 Aug; 188(4):275-88. PubMed ID: 10598685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.